Human papillomavirus vaccine Cervarix: balance of risks and benefits remains clearly positive

A safety review conducted at the end of its routine use during the ongoing human papillomavirus immunisation programme has found that no new risks have been identified for Cervarix, and that the balance of its risks and benefits remains clearly positive. Cervarix was replaced in the programme by the HPV vaccine Gardasil▼ from September 2012.